In a landmark study (1) published in Transplant International, led by Heidelberg University Hospital in Germany in collaboration with researchers from Sydney, Australia, Proenkephalin A 119-159…
Nicole Witzmann
Nicole Witzmann brings over eight years of corporate finance experience in the healthcare industry, focusing on early- and growth-stage companies. She previously served as CFO…
Follow our Journey on Social Media
View all News
Latest News
Subscribe to our Newsletter
Follow the link below to subscribe to our Newsletter & receive updates on our…
Proenkephalin A 119–159 (penKid) as a Promising New Biomarker Candidate for Early Detection of Delayed Graft Function After Kidney Transplantation
Join Dr. Christian Nußhag for a webinar where he…
Overcoming the Limitations of Acute Kidney Injury (AKI) Diagnostics in the Emergency Department: the Biomarker Proenkephalin for Early Recognition of AKI
Acute Kidney Injury is a serious…
Sepsis in the Emergency Department: Recognizing High-Risk Patients With the Biomarker Bioactive Adrenomedullin
Recognizing the high risk sepsis patients at the Emergency Department (ED) poses a…
Point-of-care Diagnostics in the Emergency Department: Better Patient Management
Near patient diagnostics can greatly improve the time to intervention and the outcomes for the severely sick patients…
Using bio-ADM and penKid for Optimization of AHF Management in Daily Clinical Practice
Acute Heart Failure (AHF) is a leading cause of hospitalization in the elderly population and it is commonly…
Using Proenkephalin as a Novel Biomarker to Estimate GFR
The standard of care to determine kidney function has significant limitations, including late detection of changes in kidney function and the…
The Implementation of a Novel Kidney Function Biomarker in Clinical Routine
Even though AKI affects 1 in 3 patients in the intensive care units, there is a significant unmet need generated by late…
